Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft

Abstract

To the Editor: Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood [1]. More than 90% of patients harbor mutations in PTPN11, KRAS, NRAS, CBL, or NF1. For most patients, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy, while relapse is the major cause of treatment failure recorded in about 35% of patients [2, 3]. Age ≥2 years, high hemoglobin F (HbF), secondary clonal aberrations, and DNA hypermethylation are associated with an increased risk of relapse [4–6]. Treatment options for recurrent JMML are limited; for patients still on immunosuppressive therapy, discontinuation of all immunosuppressing agents is generally the first intervention. Donor leukocyte infusions (DLI) can induce a response in some relapsed patients, but the overall outcome of DLI as single strategy has been unfavorable [7]. Few data are available on the efficacy and safety of second HSCT in JMML [8]. We analyzed the outcome of 68 children with JMML who relapsed after first HSCT and received a second allograft. A total of 434 patients with JMML registered in the European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS)-98/-2006 studies (ClinicalTrials.gov: NCT00047268/NCT00662090) underwent HSCT between July 1988 and January 2020. The study protocols were approved by the ethics committees of the respective institutions. Written informed consent was obtained from patients’ guardians. Of the 434 patients, 137 patients (32%) relapsed after first HSCT at a median time of 213 (range, 17–1205) days, and 78 of them (57%) received a second allograft (Supplementary Fig. 1). Most patients who did not receive a second HSCT died of disease (n = 49/59, overall survival at 5 years being 9%, Supplementary Figs. 1, 2). After the exclusion of 10 patients for insufficient data, 68 patients were included in this analysis. Outcome data of 25 patients included in this study was previously reported [8]. The median age of the 68 patients at second HSCT was 4.6 years (range, 1.0–15.8) (Table 1). Most patients (69%) harbored a somatic PTPN11 mutation (Table 1). The methylation status was analyzed as previously reported in 30 patients [9], and as expected most patients (n = 24, 80%) showed a high methylation pattern (Table 1). Of the 68 patients, 13 were treated with DLI before the second HSCT and none of them achieved remission. Nine patients received 1 to 6 cycles of azacitidine; one patient reached a clinical complete response after 6 cycles of therapy, 3 patients obtained a partial response after 3 to 5 cycles and 5 patients experienced disease progression during treatment. For second HSCT, 16 patients were transplanted from an HLA-matched sibling, 9 from a haplo-identical donor and 43 from an unrelated donor (Supplementary Table 1). In 31 cases, the same donor was used for both allografts. For the first HSCT, most patients had received a bone marrow graft and busulfan, cyclophosphamide and melphalan (Bu/Cy/Mel) as conditioning therapy. The preparative regimen for the second HSCT was based on total-body-irradiation (TBI) in 28 patients (41%), a combination of treosulfan, fludarabine and thiotepa (Treo/Flu/TT) in 14 patients (21%), or fludarabine, thiotepa and melphalan (Flu/TT/Mel) in 9 cases (17 other regimens). Sixty-one patients (90%) achieved engraftment and one of them experienced secondary graft failure. The incidence of grade II–IV and III–IV acute graft-versus-host disease (GvHD) was 52 and 22%, respectively; chronic GvHD occurred in 37% of patients (Supplementary Fig. 3) and infection was the most common complication (Supplementary Table 2). Overall, 28 patients (41%) were alive after second HSCT with a median follow-up of 7.7 years (range, 0.4–28.3). The 5-year overall survival and disease-free-survival (DFS) were 40% (27–53%) and 36% (24–48%), respectively (Supplementary Fig. 4A). Forty patients died; relapse after the second HSCT was the main cause of death (n = 23), while 17 patients died of transplantation-related causes (Supplementary Table 3). The 5-year cumulative incidence of non-relapse mortality (NRM) and relapse were 23% (15–35%) and 41% (31 to 55%), respectively (Supplementary Fig. 4B). In the univariate analysis, older age at second HSCT (≥3 years) tended to be associated with an inferior DFS (HR 1.1 [0.99–1.21], p = 0.10) (Supplementary Table 4).The presence of a PTPN11 mutation did not correlate with a worse prognosis. While 37% (9/24) of patients with a high methylation class experienced a relapse after the second allograft, none of the 6 patients with intermediate or low methylation pattern relapsed. Patients who suffered from an early relapse (<180 days after first HSCT) tended to have an inferior DFS (HR 0.6 [0.32–1.10, p = 0.10]. In the EWOG-MDS studies, the standard preparative regimen for first HSCT in JMML consists of Bu/Cy/Mel [2]. For second HSCT, many investigators had applied a TBI-regimen [8], while a non-TBI regimen has recently been preferred for second HSCT in these young patients. The probability of DFS was similar between TBI-based preparative regimens and the most recently applied Treo/Flu/TT or Flu/TT/Mel conditioning strategies in this study. (Supplementary Fig. 5). We observed 3 cases of very late NRM > 5 years after the second HSCT in association with chronic lung disease and/or chronic GvHD and/or in patients who had received a TBI-based regimen for second HSCT. Further studies are necessary to evaluate whether such late effects might be reduced by use of non-TBI regimens. The change of donor between the two allografts did not affect efficacy. There was no impact of aGvHD on DFS (grade II–IV: HR 1.3 [0.70–2.58], p = 0.37, grade III–IV: HR 1.7 [0.80–3.48], p = 0.18, n = 61 under risk). Similarly, there was no difference in DFS between patients who did or did not develop cGvHD over time (HR 0.7 [0.26–1.76], n = 47 under risk), probably due to an insufficient anti-leukemic efficacy of limited cGvHD and increased NRM with extensive cGvHD. Indeed, all events were due to NRM in patients with extensive cGvHD (5 of 8 patients, 63%) and most were due to relapse in patients with limited cGvHD (3 of 9 patients, 33%). In a multivariate Cox analysis of DFS, older was associated with worse DFS (HR 1.1 [1.00–1.22], p = 0.05, Supplementary Table 5). Table 1 Characteristics of patients with second HSCT. Patient characteristics Number of patients 68 Age at diagnosis Years, median (range) 3.0 (0.2–15.1) Gender, no. of patients (%) Male 46 (68) Female 22 (32) Karyotype at diagnosis, no. of patients (%) Normal 46 (68) Monosomy 7 14 (20) Other aberrations 7 (10) Missing data 1 (2) Mutation group, no. of patients (%) PTPN11 42 (62) NRAS 7 (10) KRAS 1 (1) NF1 7 (10) All negativea 4 (6) Missing data 7 (10) HbF <15%b 23 ≥15%c 34 Missing data 11 Methylation classes (n = 30) High 24 Intermediate 4 Low 2 Time first HSCT—relapse Days, median (range) 247 (15–788) Time first HSCT—second HSCT Days, median (range) 352 (35–907) Age at second HSCT Years, median (range) 4.6 (1.0–15.8) Time period of second HSCT, no. of patients (%) <2003 20 (29) 2003–2009 21 (31) ≥2010 27 (40) HSCT hematopoietic stem cell transplantation, HbF fetal hemoglobin. aAbsence of mutation in PTPN11, NRAS, KRAS, NF1 or CBL. bFor patients <9 months of age, HbF level was below the age-adjusted upper limit of normal. cFor patients 9 months or older age, HbF level was above the age-adjusted upper limit of normal. In conclusion, a second HSCT is feasible and can cure about one-third of patients with relapsed JMML. Because vast majority of patients who had relapse died without a second HSCT, this option should be considered for all patients with relapse. The Treo/Flu/TT preparative regimen, which EWOG-MDS currently utilizes for second HSCT, appears to be as effective as a TBI-based regimen. Further research needs to focus on pre- and post-transplantation strategies to control the nature of this aggressive neoplasm and thereby reduce relapse rates. Low-dose azacitidine has been shown to be effective and can achieve complete remission in some JMML patients prior to HSCT. Therefore, azacitidine is currently recommended as a pre-HSCT therapy [10, 11]. However, whether response to azacitidine translates into better survival rate and lower risk of relapse after HSCT needs to be evaluated further. The outcome of treatment with DLI is generally poor in relapsed JMML [7]. Further studies are warranted in order to investigate whether administration of DLI in combination with azacitidine or interferon-alpha with the goal of preventing recurrence after a second HSCT can be more effective in reducing relapse rates without increasing treatment-associated toxicity [12]. Supplementary information Supplemental Material